CD274 and non-small cell lung carcinoma: The VENTANA PD-L1 (SP263) Assay is approved for use with durvalumab treatment in urothelial carcinoma (UC) and non-small-cell lung cancer (NSCLC) and with pembrolizumab and nivolumab treatment in non-small-cell lung carcinoma [5, 6].